RNAC · Cartesian Therapeutics, Inc.
$7.14
-0.22 (-2.99%)
At close · Oct 5
Return incl. dividend (before tax)
Market Cap
$224.19M
Shares
30.26M
Volume · Oct 5
226.26K
Avg daily vol (3M)
132.69K
Price & Indicators
20d MA
50d MA
200d MA
Earnings
Filing
Insider
Congress
Investor day
Close$7.14
Open$7.36
Day$7.11–7.43
52W close$5.84–10.59
Avg vol 30d127K
Short int1.8M · 6.0% float · 17.0d
Short vol54%
Last earningsMay 8, 2025
DataJan 2020–Oct 2026
Filing10-Q · Aug 6
Up next
filed Aug 6, 2026
call held May 8, 2025
Metrics snapshot
Useful current figures from the complete screener profile.
Revenue (TTM)
$1.48M
Trailing 12 months
Net income (TTM)
−$151.89M
Trailing 12 months
Revenue growth YoY
-100.0%
Year over year
Operating margin
-10,518.6%
Trailing 12 months
P / E (TTM)
—
Trailing earnings
FCF yield
-35.1%
TTM · current market cap
Return on invested capital
—
Trailing 12 months
Net cash
—
Latest balance sheet
Dividend yield
—
Trailing 12 months
Shares change YoY
+12.9%
Year over year · more shares
Price change (1Y)
-28.8%
Trailing year
Short interest
6.0%
Latest settlement · 17.0 days to cover
Equibles Rating
blended score · not investment adviceOverall
Sell
SellHoldBuy
Technical
Sell
Momentum
Neutral
Sentiment
Bullish
Fundamentals
Poor
Quant / Vol
Very High
Market backdrop
VIX 15.5 · calm
Equity put/call 0.59
Technical
price trend
50 / 200-day cross
No cross
Price vs 200-day avg
−7%
below
Price vs 50-day avg
−16%
below
RSI (14)
30
oversold
MACD trend
Negative
52-week position
27%
mid-range
Volume (OBV)
Confirms
volume backs price
Momentum
relative strength
1-month return
−23%
trailing
6-month return
+12%
trailing
YTD return
−1%
this year
Relative strength
+1%
vs S&P · 6-mo
Sentiment
smart money
Trend (MA cross)
No cross
50d $9 › 200d $8 — 50d above 200d
Institutional flow
Accumulating
+14% holders QoQ · +25 funds added
Insider flow
Flat
No net insider activity over 90 days
Short interest
Falling
5.96% of float · ▼ -0.5% MoM · 17.0 days cover
Volume signal
Reversal watch
High volume on a down day — possible exhaustion
Institution breadth
Multi-yr high
95 holders — near 3-yr high, broad support
Squeeze score
68
elevated · 0–100
Fundamentals
Revenue growth
−93%
Y/Y
EPS growth
−12%
Y/Y
Free cash flow
$-79.4M
Quant / Vol
risk profile
Volatility
83%
annualized · 1-yr
Max drawdown
−43%
past year
ATR
6.9%
of price · 14-day
Blended from price, momentum, positioning, fundamentals & volatility · daily-close · not investment advice. Market backdrop is context, not part of the score.
Technicals
trend & momentum for long-term holders Sell
50 / 200-day cross
No cross
Neutral
Price vs 200-day avg
−7%
Bearish
Price vs 50-day avg
−16%
Bearish
RSI (14)
30
Neutral
MACD trend
Negative
Bearish
52-week position
27%
Neutral
Volume (OBV)
Confirms
Neutral
Market signals — smart money & positioning
Bullish · 3 of 6
Trend (MA cross)
No cross
50d $9 › 200d $8 — 50d above 200d
Institutional flow
Accumulating
+14% holders QoQ · +25 funds added
Insider flow
Flat
No net insider activity over 90 days
Short interest
Falling
5.96% of float · ▼ -0.5% MoM · 17.0 days cover
Volume signal
Reversal watch
High volume on a down day — possible exhaustion
Institution breadth
Multi-yr high
95 holders — near 3-yr high, broad support
Price context
position in its 52-week range
Range low $6
Now $7 · 27%
Range high $11
vs 200-day avg -7%
vs 50-day avg -16%
Illustrative technical + ownership context — a signal mix, not investment advice.
Key metrics
Earlier KPI extraction records exist, but do not meet the current evidence-completeness requirements. No current verified series is available. Earlier figures remain withheld until revalidated; this is not evidence that the company reports no KPIs.
Versus peers
Biotechnology — same industry group| Company | Mkt cap | YTD | Rev growth Y/Y | P/E | Short % shares |
|---|---|---|---|---|---|
|
RNAC
this stock
Cartesian Therapeutics, Inc.
|
$224.19M | -1.0% | -92.8% | — | 6.0% |
|
VRTX
Vertex Pharmaceuticals Inc / Ma
|
$133.37B | +11.1% | +46.2% | 30.7 | 1.9% |
|
REGN
Regeneron Pharmaceuticals, Inc.
|
$81.13B | -5.9% | +20.8% | 19.5 | 2.5% |
|
MRNA
Moderna, Inc.
|
$79.40B | +589.1% | +4.3% | — | 8.2% |
|
CSLLY
Csl Ltd
|
$61.25B | — | — | — | 0.0% |
Peers by industry group · P/E from as-reported trailing EPS · short % is of shares outstanding
At a glance
key data from every sectionOwnership
Short & Settlement
Financials
Filings
Performance
| 5D | 20D | 120D | MTD | YTD | |
|---|---|---|---|---|---|
| RNAC | -1.0% | -23.0% | +12.4% | -1.0% | -1.0% |
| SPY | +1.2% | +0.6% | +11.6% | +1.6% | +13.6% |
| vs SPY | -2.2% | -23.6% | +0.9% | -2.6% | -14.6% |